Arm Holdings plc - American Depositary Shares (ARM)

Investors are underrating the profit potential from one of the fastest-growing large caps globally.

Marvell has widened its revenue lead over the past two years, but ARM's latest quarter shows signs of acceleration that could narrow the gap.

AI is all the rage right now, but the mania could cool off quickly, without warning.

A test equipment giant's robotics arm is chasing physical AI with an early playbook that echoes Amazon's historic rise.

Treasury yields just hit a two-decade high, and I'd still rather risk it and own these three dividend stocks for the next decade.

Qualcomm signed a multiyear patent licensing deal with Huawei covering 5G, compute, and AI, facing FTC review while supporting its data center and robotics diversification strategy.

A stock with low volatility can be reassuring, but it doesn’t always mean strong long-term performance. Investors who prioritize stability may miss out on hi...

Invivyd (NASDAQ:IVVD) reported topline results from its Phase III LIBERTY study of VYD2311, an investigational low-dose intramuscular monoclonal antibody designed to prevent COVID-19, and outlined plans to pursue an accelerated-approval pathway with the U.S. Food and Drug Administration. The compan

Ford's commercial division and dealership network contrast sharply with Stellantis's lower debt, but both posted massive losses in 2025.

One specializes in AI connectivity with explosive growth but heavy customer concentration, while the other licenses foundational chip architecture with stable margins.

One is growing faster but trading at a higher valuation while sacrificing near-term profits to capture market share. The other is growing steadily, generating substantial free cash flow, and trading at a more modest premium.

Meta's new Muse agent helped lift CPU stocks, including AMD.

Kodiak Sciences (NASDAQ:KOD) reported that its Phase III DAYBREAK study met primary endpoints for two investigational treatments in treatment-naïve patients with wet age-related macular degeneration, or wet AMD, with both therapies demonstrating statistical equivalence to aflibercept on visual-acuit

What Happened? Shares of semiconductor manufacturer Vishay Intertechnology (NYSE:VSH) jumped 11.1% in the afternoon session after the company released four n...

Two of these stocks are risky bets.

One designs the chips, while the other manufactures the machines that build them. But their valuations tell a starkly different story.

Arm compounds reliably across billions of devices. Credo is posting near-triple-digit growth in AI data center connectivity. The growth gap is significant, and so is the valuation gap.

Altimmune (NASDAQ:ALT) executives outlined the company’s strategy to build a liver-disease franchise around pemvidutide, a dual glucagon/GLP-1 agonist being developed for metabolic dysfunction-associated steatohepatitis, or MASH, alcohol use disorder, or AUD, and alcohol-related liver disease, or AL

(BPT) - Erik Lofstrand never expected a routine physical to change his life. But when he was diagnosed with Type 2 diabetes, Erik suddenly found himself navigating a life-changing condition.

Ultimately, it is difficult to argue with a 251,000% lifetime return.

AMD is growing fast as the primary alternative to Nvidia in AI chips, with data center sales more than doubling year over year. Arm earns royalties across billions of devices and is finding new momentum in data centers, but its growth is more measured.

As is so often the case, the best opportunities are often hiding behind the headline name.

Oracle's AI business is booming. The question is whether its cash flow can catch up with its spending.

The ZET SCALE sales agreement removes one of the biggest obstacles to Tesla heavy truck demand.

Nebius management could decide to split the stock following a big jump in the company's stock price this year.